<DOC>
	<DOCNO>NCT01636388</DOCNO>
	<brief_summary>The investigator intend utilize reduce intensity condition allogeneic stem cell transplant EBV positive HLA match sibling unrelated adult donor combine post AlloSCT allogeneic donor derive LMP specific cytotoxic T-lymphocyte ( CTL ) infusion EBV positive patient poor risk Hodgkin Lymphoma . One three reduce intensity conditioning regimen predetermine institutional center Childhood , Adolescent Young Adult Lymphoma Cell Therapy Consortium ( LCTC ) utilize related matched unrelated adult donor allogeneic transplant follow donor LMP specific CTL infusion three dose post AlloSCT . The investigator hypothesize addition donor derive LMP specific CTLs safe feasible .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patient must 45 year age less . Patient patient 's legally authorized guardian must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) , must sign informed consent accordance institutional policy approve U.S. Department Health Human Services . Patients investigational therapy one month prior entry study . Patient must adequate organ function Adequate renal function define : Serum creatinine &lt; 2.0 x normal , Creatinine clearance radioisotope GFR &gt; 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define : Total bilirubin &lt; 2.0 x normal ; SGOT ( AST ) SGPT ( ALT ) &lt; 5.0 x normal Adequate cardiac function define : Shortening fraction &gt; 27 % echocardiogram Hodgkin Lymphoma either follow : Primary induction failure ( failure achieve initial CR ) and/or primary refractory disease.First relapse ; Early relapse ( within 12 month therapy ) ( exclude receive therapy radiation therapy initial therapy ) ; Late relapse ( great 12 month therapy ) . Only patient recurrent Stage III IV disease and/or B symptom relapse ( late relapse exclude ) ; Second relapse ; Third relapse . History prior ablative auto HSCT ineligible ablative auto HSCT â‰¥25 % residual disease least two reinduction chemotherapy cycle . EBV seropositive IgG HLA match family unrelated donor ( MUD ) HLA match family donor ( 6/6 5/6 ) match unrelated adult donor ( MUD ) ( 7/8 8/8 ) All patient enter study ideally tumor tissue original diagnostic specimen and/or relapse review centrally confirmation Hodgkin lymphoma . If specimen available , local pathology report document EBV positivity acceptable . Appropriate immunophenotyping confirm diagnosis perform . In addition , situ hybridization EBV ( LMP1 , and/or EBER positivity ) perform . All central morphologic analysis immunohistochemical/insitu hybridization stain perform laboratory Sherrie Perkins Rodney Miles University Utah . Patients HD 4th great CR , PR , and/or SD ineligible . Patients rapidly progressive disease ( PD ) unresponsive reinduction chemo , radio , immunotherapy ineligible . EBV negative Hodgkin Lymphoma . Patients n't eligible donor ( outlined 7.0 ) ineligible . Women pregnant ineligible . Negative pregnancy test woman childbearing age require .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsed Hodgkins Lymphoma</keyword>
	<keyword>Refractory Hodgkins Lymphoma</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Adoptive Immunotherapy</keyword>
	<keyword>Cellular Therapy</keyword>
	<keyword>Cytotoxic T cell lymphocyte</keyword>
</DOC>